Shuttle Pharmaceuticals Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Shuttle Pharmaceuticals Holdings reports a net loss of $9.1 million for 2024 and acknowledges substantial doubt about its ability to continue as a going concern without additional financing.
NASDAQ
Shuttle Pharmaceuticals Holdings, Inc. has amended its annual report to restate its financial statements for 2022 and 2023 due to accounting errors and material weaknesses in internal controls.
NASDAQ
10-K: Shuttle Pharmaceuticals Reports Full Year 2023 Results, Advances Ropidoxuridine Clinical Program
Shuttle Pharmaceuticals reports a net loss of $6.6 million for 2023, while advancing its lead drug candidate, Ropidoxuridine, to a Phase II clinical trial.